MedTrace Logo

Impact of Two Guided Transfusion Strategies on Blood Product Requirements in Liver Transplantation.

NCT04405518 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 188

Last updated 2021-11-26

No results posted yet for this study

Summary

It is a national multicentre clinical study, where 3 hospitals are involved: Bellvitge University Hospital, Clinic Hospital of Barcelona and Cruces Hospital of Bilbao). It is a randomized study based on the Hemoglobin value of the patient with a 1:1 ratio, parallel groups, controlled and single blind, in patients undergoing an orthotopic liver transplant, confirming previously that the participants fulfill all the inclusion criteria and none of exclusion.

Conditions

  • Fibrin Blood Clot

Interventions

DRUG

Fibrinogen Concentrate (Human) 1 MG [RiaSTAP]

The drug used in this study is Riastap, 1g (Fibrinogen). The dose administered will depend on the arm group assigned and in the results of the thromboelastogram during the procedure.

Sponsors & Collaborators

  • Antoni Sabaté Pes

    lead OTHER

Principal Investigators

  • Marta Caballero · Bellvitge University Hospital

  • Josep Beltran · Clinic Hospital, Barcelona

  • Rosa Gutierrez · Cruces Hospital, Bilbao

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-17
Primary Completion
2021-11-02
Completion
2022-10-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04405518 on ClinicalTrials.gov